Small Cap Feast
Small Cap Feast – 27 November 2018
Set Menu AIM:
Total number of AIM Companies (Incl Susp): 920
Total number of AIM Companies trading: 850*
* As at 26 November 2018
Set Menu NEX Growth:
Total number of NEX Growth Market Companies (Incl Susp): 89*
Total number of NEX Growth Market Companies trading: 87*
* As at 26 November 2018
Set Menu Standard List:
Total number of Standard List Companies (Incl Susp): *
Total number of Standard List Companies trading: *
* As at 26 November 2018
Dish of the Day:
No Joiners Today
No Joiners Today
Off the Menu:
No Leavers Today
No Leavers Today
Dish of the Day:
No Joiners Today
No Joiners Today
Off the Menu:
No Leavers Today
No Leavers Today
What’s Cooking in the IPO Kitchen?
Main Market (Premium)
SEEIT will be the first UK-listed investment fund of its kind to invest exclusively in the energy efficiency sector. Looking to raise £150m. Due 11 Dec
AJ Bell—one of the largest investment platforms in the UK—Expects to publish prospectus end Nov. FYSep18—revenues up 19% to £89.7 million, profit before tax up 31% to £28.4 million. Secondary sell down, Due December.
Sirius Aircraft Leasing Fund targeting a raise of US$250m – objective is to provide investors with an attractive level of regular income and capital returns through investing primarily in used, single-aisle aircraft. Due 5 Dec
MOD Resources—(ASX:MOD) A$78.7m mkt cap. Copper exploration and development company focused on the central and western Kalahari Copper Belt in Botswana. Introduction only. Due c.26 Nov.
Main Market (Specialist Funds)
The Global Sustainability Trust -aiming for attractive risk-adjusted returns by investing primarily in private market investments that are expected to have a positive environmental and social impact raising c.£200m. Due end Nov.
Kropz, an emerging plant nutrient producer with an advanced stage phosphate mining project in South Africa, a phosphate project in the Republic of Congo and exploration assets in Ghana, is looking to join AIM. Offer TBC, expected late Nov
Titon holdings—international manufacturer and supplier of ventilation systems and window and door hardware. No capital raise. Due 10 Dec. Mkt cap c.£22m.
Greenfields Petroleum (TSX-V:GNF) production focused company with operated assets in Azerbaijan seeking AIM dual listing including $60m private placement. Mkt cap $12.6m CAD. Expected early December.
Finncap—proposed acquisition of M&A adviser Cavendish Corporate Finance and AIM admission. Offer TBA. Due early Dec
Crossword Cybersecurity PLC* (NEX:CCS)—the technology commercialisation company focusing exclusively on the cyber security sector is investigating the possibility of AIM admission. The Company is proposing to raise up to £2.25 million before the end of December, conditional on Admission.
The Panoply parent company of a digitally native technology services group founded in 2016 with the aim of identifying and acquiring best-of-breed specialist information technology and innovation consulting businesses across Europe, is looking to join AIM. Offer £5m new capital, £400k sell-down, market cap of £30m, expected late 4 Dec 2018.
President Energy (PPC.L) 9.35p £98.7m
President Energy, the upstream oil and gas company with a diverse portfolio of production and exploration assets focused primarily in Argentina, provides an update on its current drilling programme at the Puesto Flores/Estancia Vieja Concession in Rio Negro Province, Argentina (President 90% and operator – Edhipsa 10%).
The PFO 1005 development well at the Puesto Flores field, being the last of the recent three well sequence, has now been spudded. With a provisional target depth of 2,700 metres, it is estimated that the well will be drilled in approximately 21 days.
The recently drilled PFE 1001 well is expected to be completed with a work over rig and be on stream by the end of next week.
Inland Homes (FRR.L) 0.35p £57.98m
Inland Homes, a leading housebuilder, Partnership Housing developer and regeneration specialist, provides the following statement ahead of its AGM , 27 Nov 2018, at 11am.
The Group’s strategy to focus on affordably priced, good quality homes for sale in the South East of England, Partnership Housing and land trading is providing a platform for strong operational and financial performance during the rest of the financial year.
Our most recent initiatives, Rosewood Housing and Hugg Homes, will enable us to further reinforce our affordable housing offering and capture additional value from our assets. Both are expected to begin delivering recurring income later this financial year.
The first five months of the current financial year have been in line with our expectations.
OPG (OPG.L) 30.5p £13.94m
OPG, the developer and operator of power generation plants in India, announces its unaudited results for the six months ended 30 Sept 2018.
H1 FY19 total generation of 1.55 billion units up 9 per cent from 1.42 billion units in H1 FY18
Robust operational performance – PLF at Chennai 85% in H1 FY19; 73% in H1 FY18
Chennai average tariff in H1 FY19 was Rs5.20, Rs4.92 in FY18
Profit from continuing operations was £6.5m compared with £2.1m in H1 FY18
Average tariff increase of 7% to Rs5.58 effective from Oct 2018 for captive consumers
Coal prices have reduced by 23% since end of Sept 2018
£10.3m term loan principal repayment in H1 FY19; Gross debt £85.9m, incl. term loans of £76.5m and working capital loans of £9.4m
Novacyt (NCYT.L) 53.5p £45.08m
Novacyt, an international specialist in clinical diagnostics, announced its molecular testing division, Primerdesign Ltd., has signed an exclusive supply agreement worth a minimum of $3m with Genesis Diagnostics, a US-based full service diagnostic laboratory that offers clinical diagnostic testing, oral fluid drug testing and services focused on drug monitoring, substance abuse programmes, infectious disease, and personalised medicine.
Primerdesign will develop and supply 384 well plate molecular assay panels for respiratory, women’s health, sexually transmitted, wound and urinary tract infections for Genesis Diagnostics to use in its clinical service laboratory based in Langhorne, Pennsylvania.
Under the terms of the agreement, Primerdesign will be appointed the exclusive product manufacturer of the panel for a minimum of five years. The supply of product is expected to commence in early 2019 and Genesis Diagnostics will purchase minimum quantities of product to the value of $600,000 per year.
Allergy Therapeutics (AGY.L) 15.75p £100.2m
Allergy Therapeutics, the fully integrated commercial biotechnology company specialising in allergy vaccines, provided an AGM trading and regulatory update ahead of its Half Year Results to be announced in March 2019.
The Group continues to perform well with revenues up strongly from the prior year in most markets and sales in line with market expectations for the year. The Group continues to gain market share in Europe, particularly in Germany.
The Group continues to prepare for the upcoming PQ Grass pivotal Phase III trial that can allow for US registration. An end of Phase II meeting with the FDA has now been confirmed for Jan 2019 and good progress is being made regarding the Phase III trial protocol. Further to previous updates, top line results from the PQ Birch (B301) Phase III trial for Europe are now expected in Q1 2019. Allergy Therapeutics remains blinded to the data package and looks forward to the disclosure of the data.
The Worthing site recently completed a successful MHRA audit with no critical findings illustrating the quality of the Group’s supply chain.
C4X Discovery (C4XD.L) 87p £49.7m
C4X Discovery, a pioneering drug discovery company, announced that it has entered into a discovery partnership with LifeArc®, one of the UK’s leading medical research charities. C4XD and LifeArc will join forces to progress medicinal chemistry efforts on a novel, commercially attractive programme with applicability across oncology and inflammation indications. The undisclosed target originated from LifeArc’s extensive partnerships in early-stage academic research.
The partnership will combine leading drug discovery expertise from both organisations, including application of C4XD’s unique and proprietary ligand-focussed conformational analysis platform, Conformetrix, to LifeArc’s extensive background and experience in the programme. This discovery partnership adds a high value programme to C4XD’s portfolio. Furthermore, it demonstrates continued progress against its stated strategy of utilising its cutting-edge drug discovery engine, and establishing productive partnerships, to develop novel small molecules against targets with high partnering interest.
Terms of the agreement are undisclosed.
Ace Liberty and Stone (NEX:ALSP) 105p £43.3m
Ace Liberty and Stone, the active property investment company, capitalising on commercial property investment opportunities across the UK, announced that it has completed the purchase of Mecca Bingo Hall in Chesterfield for a total consideration of £4m; the asset is expected to generate an income of £0.39m per annum.
The property, which is let to Mecca Bingo Ltd for the next 10 years, occupies a large site west of Chesterfield town centre and is close to large blue chip consumer retailer Lidl. Other retail warehouse occupiers within the vicinity include Wickes, Carpetright and Matalan. Furthermore, the principal out of town Retail Park for Chesterfield is situated close by on Ravenside Retail Park, where retailers include Next, B&M, Asda Living and Currys. The new 10 year re-gear of the lease illustrates the strength of the unit’s trading performance and Mecca’s commitment to the property.
Furthermore, Premier Inn is due to open a brand new hotel in Chesterfield in Jan 2019. Situated in the Mock-Tudor former department store and located firmly in the town centre, the hotel will house 92 beds with the development more widely set to showcase seven new bars and restaurants.
Altitude Group (ALT.L) 85p £46.92m
Altitude Group, the operator of a leading marketplace for personalised products, provided an operational update for the 9-week period since the Interim Results announcement on 25 Sept 2018, ahead of the Group’s CEO, Nicole Stella, presenting at a Mello investor event at Clayton Hotel, Chiswick, London later today.
AIMPro summary of progress
As at 18 November 2018:
Blended average transaction fees running at 2.4% of sales order value over last 12 weeks (for member control cohort)
75% of Members Processing Orders (“MPO’s”) have placed repeat orders (up from 73%)
47% growth in MPO’s to 240 in the last 9 weeks (up from 164)
41.3% growth in the number of sales orders processed to 15,722 in last 9 weeks (up from 11,123)
35% growth in the value of sales orders processed to $13.4m in last 9 weeks (up from $9.9m)
65% of AIM’s 1,904 members are now actively engaging with our US customer success team
Current sales order value per week (8-week average) $675k (up from $487k)
1,254 live e-commerce websites built (up from 1,000)
AIM membership increased to 1,904 (up from 1,857) representing aggregate annual revenues of approximately US $1.7bn
HML Holdings (HMLH.L) 30.5p £13.94m
ML Holdings, the property management services group, announced its interim results for the six months to 30 Sept 2018.
Revenue up 7% to £13.6m (2017: £12.7m)
11% increase in profit from operations before interest, amortisation, share based payment charges and taxation to £1.12m (2017: £1.01m)
Cash generated from operations was £1.56m (2017: £1.04m)
Adjusted EPS 2.2p (2017: 1.9p).
Net debt reduced to £0.96m (2017: £1.47m)
Savannah Resources (SAV.L) 6.1p £53.77m
Savannah Resources, the resource development company, announced the appointment of James Leahy as an Independent NED with immediate effect. With more than 32 years’ experience in financial services, Mr Leahy has an extensive understanding of capital markets with a specialisation in commodities. In addition, Mr Leahy has executive experience having acted as Interim Chairman for Bacanora Minerals Ltd, a publically listed company and served on the boards of several listed and private companies. In these positions, he also sat on various committees ranging from audit and remuneration to AIM compliance and special Investigations. Mr Leahy will join Savannah’s Audit and Risk Committee and Remuneration Committee.
0203 764 2344
*A corporate client of Hybridan LLP
This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.
The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.
The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).
Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.
This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.
In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.
Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.
Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.
Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.
This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.
MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.
If you would like to unsubscribe, please email email@example.com with “unsubscribe me”.